MariTide Aims to Disrupt Obesity Market with Convenient Dosing

Amgen's MariTide is gaining attention as a potential game-changer in the obesity market. This drug, currently in phase III trials, combines GLP-1 receptor activation with GIP receptor blockade and is designed for less frequent dosing, which could improve patient persistence on treatment.

MariTide has shown promising results in phase II studies, with patients achieving up to 20% average weight loss over 52 weeks without reaching a plateau. The drug is being evaluated in type II diabetes, obesity, and related conditions as part of Amgen's comprehensive MARITIME program.

Despite trailing behind industry leaders Eli Lilly and Novo Nordisk in the obesity market, Amgen's MariTide could carve out a niche around convenience, adherence, and durability. With less frequent dosing, MariTide may appeal to patients who struggle with the current weekly injection regimens of Wegovy and Zepbound.

The global obesity drug market is projected to reach nearly $114 billion by 2030, according to Goldman Sachs estimates. Amgen's entry into this market could be significant, especially if MariTide can demonstrate long-term efficacy and patient compliance.